Inventiva S.A.
corporate_fare Company Profile
Inventiva S.A. (NASDAQ:IVA) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 19 items for IVA at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-09-28, rated 8/10. Across its 19 most recent items scored 7 or higher, the top rating is 9/10, with 12 rated 8 or above. Recent SEC coverage for IVA spans 6-K, 6-K/A, 424B5, FWP.
Recent high-impact activity:
- Inventiva's Full H1 2026 Report Flags Going Concern, Cash Runway to Q2 2027, and 31.6% Potential Dilution
- Inventiva Completes Final Patient Visit in NATiV3 Phase 3 Trial; Topline Data Due Q4 2026
- Inventiva Corrects Tranche C Debt Financing Proceeds to €55M, Extending Cash Runway to Q1 2028
- Inventiva Reports H1 2026 Cash of €234M, Extends Runway to Q2 2027 After June Refinancing
- Inventiva wraps up EIB warrant restructuring with 15.7M new warrants at a €0.01 strike
Financial Snapshot
Short Interest & Short Volume
3.50 days to coverFINRA reported short interest of 10,345,024 shares in IVA as of the October 30, 2026 settlement, a 26.9% increase from the prior period — about 3.5 days to cover at its recent average daily volume. On November 20, 2026, 43.1% of IVA volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
High riskFiling-implied dilution signals for IVA, detected from its recent SEC filings · based on capital-structure filings through 2026-07-09.
Significant Equity Offering Priced · Addresses Going Concern Warning
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →
Insider Transactions
IVA files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.